GLP-1 receptor agonists (GLP-1RAs), including semaglutide and liraglutide, are already approved for treating type 2 diabetes and obesity [31,32,33,34,35,36,37,38,39]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.